Literature DB >> 30142130

Impact of Exercise Training on Cardiac Function Among Patients With Type 2 Diabetes: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Vidhu Anand1, Sushil Garg, Jalaj Garg, Shah Bano, Marc Pritzker.   

Abstract

PURPOSE: Type 2 diabetes (T2D) is associated with subclinical abnormalities in left ventricular function and an increased downstream risk for heart failure. Exercise training has been associated with significant improvement in cardiorespiratory fitness among these patients. However, its impact on cardiac function is not well established.
METHODS: We conducted a meta-analysis including all randomized and nonrandomized trials that evaluated effects of exercise training on cardiac function among patients with T2D. Primary outcomes were measures of left ventricular systolic (global longitudinal strain) and diastolic (early diastolic velocity [é]) function. The effects of exercise training on peak oxygen uptake; other markers of diastolic dysfunction: mitral peak early-to-late diastolic filling velocity (E/A), mitral inflow to annular ratio (E/é), and deceleration time (DT); and systolic velocity were also assessed.
RESULTS: Our study included 441 patients enrolled in 6 trials. Exercise training significantly improved early diastolic velocity (standardized mean difference [SMD], 0.58; 95% CI, 0.09-1.07), global longitudinal strain (SMD, 0.62; 95% CI, 0.04-1.21), and peak oxygen uptake (SMD, 1.43; 95% CI, 0.51-2.35) as compared with control group. However, no significant changes were observed in other markers of diastolic function (E/A, E/é and DT) and systolic velocity.
CONCLUSION: Exercise training in patients with T2D is associated with a significant improvement in some echocardiographic indicators of systolic and diastolic function and cardiorespiratory fitness. These findings suggest that exercise training may improve subclinical systolic and diastolic dysfunction in patients at risk for clinical heart failure.

Entities:  

Mesh:

Year:  2018        PMID: 30142130     DOI: 10.1097/HCR.0000000000000353

Source DB:  PubMed          Journal:  J Cardiopulm Rehabil Prev        ISSN: 1932-7501            Impact factor:   2.081


  4 in total

1.  The effects and acceptability of different exercise modes on glycemic control in type 2 diabetes mellitus: A protocol for systematic review and network meta-analysis.

Authors:  Yuanlong Shen; Lina Yu; Zhen Hua; Ningxin Jia; Yanan Zhou; Xiaosheng Dong; Meng Ding
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

2.  Remission of type 2 diabetes and improved diastolic function by combining structured exercise with meal replacement and food reintroduction among young adults: the RESET for REMISSION randomised controlled trial protocol.

Authors:  Kaberi Dasgupta; Thomas Yates; Normand Boulé; Joseph Henson; Stéphanie Chevalier; Emma Redman; Deborah Chan; Matthew McCarthy; Julia Champagne; Frank Arsenyadis; Jordan Rees; Deborah Da Costa; Edward Gregg; Roseanne Yeung; Michelle Hadjiconstantinou; Abhishek Dattani; Matthias G Friedrich; Kamlesh Khunti; Elham Rahme; Isabel Fortier; Carla M Prado; Mark Sherman; Richard B Thompson; Melanie J Davies; Gerry P McCann
Journal:  BMJ Open       Date:  2022-09-21       Impact factor: 3.006

3.  Type 2 diabetes and reduced exercise tolerance: a review of the literature through an integrated physiology approach.

Authors:  Lorenzo Nesti; Nicola Riccardo Pugliese; Paolo Sciuto; Andrea Natali
Journal:  Cardiovasc Diabetol       Date:  2020-09-05       Impact factor: 9.951

4.  Type 2 diabetes is an independent predictor of lowered peak aerobic capacity in heart failure patients with non-reduced or reduced left ventricular ejection fraction.

Authors:  Takahiro Abe; Takashi Yokota; Arata Fukushima; Naoya Kakutani; Takashi Katayama; Ryosuke Shirakawa; Satoshi Maekawa; Hideo Nambu; Yoshikuni Obata; Katsuma Yamanashi; Ippei Nakano; Shingo Takada; Isao Yokota; Koichi Okita; Shintaro Kinugawa; Toshihisa Anzai
Journal:  Cardiovasc Diabetol       Date:  2020-09-19       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.